Recent studies by various researchers show that new biomarkers have the potential to improve the location and prediction of prostate, colorectal, and lung cancers, according to Forbes.com. In one study, German researchers found two new genes that will help in the diagnosis and treatment of colorectal cancer. A second study done at Yale showed that the levels of a protein called thymidylate synthase (TS) in blood could be beneficial in predicting life expectancy after having survived colorectal cancer. A third study led by investigators at Panacea Pharmaceuticals is working with a specific blood protein [human aspartyl (asparaginyl) beta-hydroxylase] to improve prostate cancer treatments. And in yet another study, Purdue University researchers have found a protein in the blood that could improve the ways that prostate cancer growth is monitored.